Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome

International Journal of Clinical Oncology

Volumn 19, Issue 1, 2014, Pages 10-15

  Ishikawa, Takayuki ^a  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

Author keywords

Azacitidine; Decitabine; Hypomethylating agents; Myelodysplastic syndrome

Indexed keywords

AZACITIDINE; BENZAMIDES; DNA METHYLATION; HUMANS; MOLECULAR TARGETED THERAPY; MYELODYSPLASTIC SYNDROMES; PIPERAZINES; PYRIMIDINES; THALIDOMIDE;

EID: 84894525183     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-013-0651-5     Document Type: Review

References (43)

1. Tefferi A, Vardiman JW (2009) Myelodysplastic syndromes. N Engl J Med 361:1872-1885
2. Greenberg PL, Tuechler H, Schanz J, et al. (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454-2465
3. Parmar S, de Lima M, Deeg HJ, et al. (2011) Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review. Semin Oncol 38:693-704
4. Von Hoff DD, Slavik M, Muggia FM (1976) 5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Intern Med 85:237-245
5. Momparler RL, Rivard GE, Gyger M (1985) Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia. Pharmacol Ther 30:277-286
6. Constantinides PG, Jones PA, Gevers W (1977) Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment. Nature 267:364-366
7. Compere SJ, Palmiter RD (1981) DNA methylation controls the inducibility of the mouse metallothionein-I gene lymphoid cells. Cell 25:233-240
8. Pinto A, Attadia V, Fusco A, et al. (1984) 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 64:922-929
9. Silverman LR, Holland JF, Weinberg RS, et al. (1993) Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7(Suppl 1):21-29
10. Zagonel V, Lo Re G, Marotta G, et al. (1993) 5-Aza-2′-deoxycytidine (decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia 7(Suppl 1):30-35
11. Silverman LR, Demakos EP, Peterson BL, et al. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20:2429-2440
12. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223-232
13. Fenaux P, Gattermann N, Seymour JF, et al. (2010) Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol 149:244-249
14. Seymour JF, Fenaux P, Silverman LR, et al. (2010) Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 76:218-227
15. Lubbert M, Wijermans P, Kunzmann R, et al. (2001) Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 114:349-357
16. Kantarjian H, Issa JP, Rosenfeld CS, et al. (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106:1794-1803
17. Lubbert M, Suciu S, Baila L, et al. (2011) Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 29:1987-1996
18. Kantarjian HM, O'Brien S, Shan J, et al. (2007) Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 109:265-273
19. Uchida T, Ogawa Y, Kobayashi Y, et al. (2011) Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes. Cancer Sci 102:1680-1686
20. Lyons RM, Cosgriff TM, Modi SS, et al. (2009) Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 27:1850-1856
21. Musto P, Maurillo L, Spagnoli A, et al. (2010) Azacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an Italian named patient program. Cancer 116:1485-1494
22. Fili C, Malagola M, Follo MY, et al. (2013) Prospective phase II study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes. Clin Cancer Res 19:3297-3308
23. Itzykson R, Thepot S, Quesnel B, et al. (2011) Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 117:403-411
24. Prebet T, Gore SD, Esterni B, et al. (2011) Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 29:3322-3327
25. Yang H, Hoshino K, Sanchez-Gonzalez B, et al. (2005) Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk Res 29:739-748
26. Garcia-Manero G, Yang H, Bueso-Ramos C, et al. (2008) Phase 1 study of the histone deacetylase inhibitor vorinostat [suberoylanilide hydroxamic acid (SAHA)] in patients with advanced leukemias and myelodysplastic syndromes. Blood 111:1060-1066
27. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. (2006) Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 108:3271-3279
28. Platzbecker U, Braulke F, Kundgen A, et al. (2013) Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. Leukemia 27:1403-1407
29. Sekeres MA, List AF, Cuthbertson D, et al. (2010) Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 28:2253-2258
30. Sekeres MA, Tiu RV, Komrokji R, et al. (2012) Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood 120:4945-4951
31. Zeidan AM, Linhares Y, Gore SD (2013) Current therapy of myelodysplastic syndromes. Blood Rev 27:243-259
32. Borthakur G, Huang X, Kantarjian H, et al. (2010) Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma 51:73-78
33. Bayraktar UD, Domingo GC, Schmit J, et al. (2011) Azacitidine combined with gemtuzumab ozogamicin in patients with relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 52:913-915
34. Kantarjian HM, Giles FJ, Greenberg PL, et al. (2010) Phase II study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 116:3163-3170
35. Greenberg PL, Garcia-Manero G, Moore M, et al. (2013) A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. Leuk Lymphoma 54:321-328
36. Scott BL, Storer B, Loken MR, et al. (2005) Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 11:65-73
37. Nakai K, Kanda Y, Fukuhara S, et al. (2005) Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 19:396-401
38. Damaj G, Duhamel A, Robin M, et al. (2012) Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol 30:4533-4540
39. Gerds AT, Gooley TA, Estey EH, et al. (2012) Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant 18:1211-1218
40. de Lima M, Giralt S, Thall PF, et al. (2010) Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 116:5420-5431
41. Schroeder T, Czibere A, Platzbecker U, et al. (2013) Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 27:1229-1235
42. Estey EH (2013) Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia 27:1803-1812
43. Ogawa S (2012) Splicing factor mutations in myelodysplasia. Int J Hematol 96:438-442